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Phenotype of pulmonary hypertension in patients with heart failure 
and preserved ejection fraction
Nathanaël Auquier [Orateur], Baptiste Kurtz, Charlotte Vallet, Bertrand 
D’Héré, Dimitri Stepowski, Hélène Eltchaninoff, Fabrice Bauer
Hôpital Charles Nicolle, Rouen, France
Background: Because pulmonary hypertension (PH) seriously worsens 
prognosis of patients with Heart failure and preserved ejection fraction 
(HFPEF), new drugs are currently being tested to improve hemodynamic and 
outcomes. The purpose of this work is to establish the prevalence and deter-
minants of PH in patients with HFPEF. 
Methods: Between 01/12/2008 and 06/12/2011, we prospectively included 
patients with HFPEF recently discharged from hospital for worsening heart 
failure (Framingham criteria, BNP>100, EF>50%). Two months later, all 
patients underwent a full echocardiography study. Patients were dichotomized 
from the tricuspid regurgitation peak velocity (TRV < 3m/s or TRV >3m/s i.e. 
high prevalence of PH). 
Results: From 67 patients with HFPEF, 7 patients had undetectable TRV. 
Of the 60 remaining patients, 20 (33%) had TRV<3m/s and 40 (67%) had 
TRV>3m/s. Weight (p=0.03, r=- 0.27), E velocity (p=0.002, r=+0.38), E/A 
(p=0.02  , r=+0.38) both septal (p=0.02 , r=- 0.29) and posterior wall (p=0.04, 
r=- 0.26)thickness, hemoglobin (p=0.02, r=- 0.30), calcium blocker (p=0.05, 
 r=- 0.25) were univarietely but not independently correlated to TRV. From 
multiple regression analysis, the four residual determinants of TVR were 
weight (p=0.003), E velocity (p=0.03), parietal thickness (p=0.03) and calcium 
blocker administration (p=0.03).
Conclusion: Pulmonary hypertension is prevalent in patients with HFPEF. 
Pulmonary hypertension in HFPEF is correlated to weight, E velocity, parietal 
thickness and calcium blocker prescription.
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MRI Late- enhancement is not correlated to prognosis in patients with 
heart failure and preserved ejection
Dimitri Stepowski [Orateur], Bertrand D’Héré, Baptiste Kurtz, Charlotte 
Vallet, Vincent Richard, Nathanaël Auquier, Hélène Eltchaninoff, Jean 
Nicolas Dacher, Jérome Caudron, Fabrice Bauer
Hôpital Charles Nicolle, Rouen, France
Background: Heart failure with preserved ejection fraction (HFPEF) is 
correlated to ¿ brosis accumulation in the myocardium. As a marker of ¿ brosis, 
we correlated MRI late enhancement to prognosis in HFPEF. 
Methods: 50 patients with Framingham criteria of acute decompensated 
heart failure, elevated BNP level and EF >50% had MRI examination and 
echocardiography study after 2 months of clinical stabilization. Late enhance-
ment was visually assessed 10 minutes after gadolinium injection and patients 
were followed- up during 1 year for death and HF readmission. Mean age was 
74±10y. There were 28 women (56%). 26 patients were in atrial ¿ brillation. 
Ejection fraction was 59±10%. Late enhancement was detected in 19 patients. 
12 patients reached an endpoint (2 deaths and 10 readmissions for HF). From 
the tested parameters including late MRI late- enhancement, none were uni-
varietely or multivarietely correlated to prognosis and the cox proportional 
hazard ratio was not statistically signi¿ cant (p=0.37). The ¿ gure shows the 
Kaplan Meyer survival curve. 
Conclusion: MRI Late enhancement has no prognostic signi¿ cance in 





















Log Rank test p = 0,3




Interest of cardiopulmonary exercise testing in patients with heart fail-
ure and preserved ejection fraction
Baptiste Kurtz [Orateur], Bertrand D’Here, Dimitri Stepowski, Anne Marie 
Mutel, Charlotte Vallet, Eltchaninoff Helene, Fabrice Bauer
Department of Cardiology, Rouen University Hospital, INSERM 1096, 
Rouen, France
Background: Cardiopulmonary exercise testing (CPX) has proven to be 
a valuable tool for assessing prognosis in patients with systolic heart failure 
(HF). We sought to evaluate CPX in a population of patients with heart failure 
and preserved ejection fraction (HFPEF).
Methods: We prospectively included patients with HFPEF recently dis-
charged from hospital for worsening heart failure (Framingham criteria, 
BNP>100pg/ml, EF>50%). Thirty ¿ ve patients were enrolled in the study and 
underwent CPX within 2 months after discharge. Patients were followed for 
death and/or hospitalisation for HF. We examined CPX related variables and 
their ability to predict mortality and/or hospitalization for worsening HF.
Results: Four patients were hospitalized for worsening HF during the 
follow up period (mean: 282±117 days) and there was no death. The VE/
VCO2 slope (table) was signi¿ cantly higher in the group of patient with an 
event compared to that in the group without event (p=0.016). Heart rate reco-
very tended to be signi¿ cantly lower in the group with an event (p=0.047). 
There was no difference between groups in terms of other tested variables 
especially peak VO2 (p=0.5). However, real peak was dif¿ cult to obtain in 
that elderly population (73±10 year) because of sub maximal CPX.
Conclusions: The majority of literature supporting the value of CPX has 
been performed in patients with HF and systolic dysfunction. We demons-
trated that CPX has promise in the evaluation of patients with HFPEF. VE/
VCO2 slope may be a signi¿ cant predictor of hospitalization for worsening 
heart failure in HFPEF patients.






Peak VO2 (mlO2.min-1.kg-1) 15.4±6.6 13.2±2.8 0.5
Ve/VCO2 slope 32.7±4.8 39.5±7 0.016
Heart rate recovery (bpm) 15±12 3±3 0.047
O2 pulse 0.13±0.05 0.14±0.02 0.57
PetCO2 (mmHg) 37.8±4.8 33.3±4.9 0.08
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Mechanisms leading to Heart Failure in the context of Metabolic Syn-
drome in the SHHF rat model
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Carlos Labat (1), Peter Nazarov (3), Patrick Lacolley (1), Faiez Zannad (4), 
Laurent Vallar (3), Anne Pizard (1)
(1) UMRS 961, Inserm, Vandoeuvre- Lès- Nancy, France - (2) EA 4438 
Neurobiologie et Pharmacologie cardiovasculaire, Strasbourg, France 
- (3) microarray center, CRP- Santé, Luxembourg, Luxembourg - (4) CIC- 
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Heart failure (HF) is one of the leading causes of mortality in the world. 
The association of several risk factors (including Obesity, Hypertension, 
Insulin resistance) grouped under the name Metabolic Syndrome (MetS) is 
known to increase the incidence of HF. Elucidating the signaling pathways 
leading to HF development of in the context of MetS especially the one regu-
lated by microRNA (miR) should unravel new diagnostic tools and therapeutic 
targets to prevent both diseases.
Methods and results: To elucidate the pathways altered in MetS that 
inÀ uence the HF development, Spontaneously Hypertensive Heart Failure rats 
(SHHF/Mccfacp) known to develop HF in association (obese: cp/cp) or not 
(lean: +/+ and cp/+) with MetS were fed with a high- fat diet (Purina 5008) 
and phenotyped during the progression of HF (from 6w to 11mo of age). We 
observed that: i) Obesity of the cp/cp rats is phenotyped as early as 6w of age 
ii) SHHF lean and obese are hypertensive (Plethysmography) but only obese 
rats kept signi¿ cantly increasing blood pressure overtime, iii) by 4mo Kidney 
function (urinary volume, ionogram composition, osmolarity) is altered in cp/
cp rats compared to the lean ones iv) while lean and obese rats reduce their 
myocardial function overtime (diminished ejection fraction and fraction shor-
tening, an increase of the relaxation time of the left ventricle), cardiac echo-
graphy reveals that as early as 6w, obese rats present a signi¿ cant higher left 
ventricular mass and volume v) plasmatic miR expression pro¿ ling (qPCR 
using Taqman® MicroRNA Array) reveals at 6mo a strong expression in 
obese rats of miRs identi¿ ed in metabolic disorders and heart disease (inclu-
ding miR- 122 and miR- 21 respectively)
Conclusion: While still investigating the molecular signaling involved in 
the progression to HF, our preliminary results suggest that the pathways trig-
gering the onset of the disease might have been turned on as early as 6w of 
age and are inÀ uenced by metabolic parameters.
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Developing models of cardiomyopathies in zebra¿ sh suitable for drug 
screening
Caroline Ramspacher [Orateur], Karim Hnia, Jocelyn Laporte, Julien 
Vermot
IGBMC, Illkirch- Graffenstaden, France
    Cardiomyopathy de¿ nes a heterogenous group of neuromuscular diseases 
targeting the myocardium and leading to abnormal heart contractions. Among 
them, desminopathy is a genetically inheritated (autosomal dominant or reces-
sive) dilated myopathy caused by a mutation in the desmin gene or in the 
alphaB- cristallin gene. It is characterized by the presence of desmin aggre-
gates in muscle cells. Desminopathies are amongst the most common interme-
diate ¿ lament human disorder and more than 40 mutations in the desmin gene 
have been identi¿ ed so far to cause myo¿ brillar myopathy.
    Desmin is the muscle- speci¿ c member of the intermediate ¿ lament 
family of cytoskeleton protein. In human, mutation in desmin gene induces 
dilated cardiomyopathy of type 1. This condition enlarges and weakens the 
cardiac muscles, preventing it from pumping ef¿ ciently leading to reduced 
systemic output, conduction blocks, arrhythmias and chronic heart failure. 
Desmin mutations also cause another form of cardiomyopathy called restric-
tive myopathy in which heart muscle is stiff and cannot fully relaxed after 
each contraction.
    We aim at generating an animal model of desminopathy by overexpres-
sing mutated versions of the human desmin gene in zebra¿ sh. This animal 
model constitutes a powerful tool for ef¿ cient genetic labeling and high reso-
lution imaging allowing detailed analysis of in vivo ¿ ber assembly, myocar-
dial cell dynamics and myocardial contraction during heart development.
   We characterized the roles of desmina, the homologue of desmin in 
zebra¿ sh, during embryonic development. We will present data showing that 
desmina zebra¿ sh morphant and mutant embryos present multiple develop-
mental defects affecting myocardial development and function as well as peri-
pheric defects affecting the vascular system.
   On the long run, zebra¿ sh models of desminopathy will be used in a drug 
screening step for determination of drugs rescuing the class of phenotypes we 
are currently characterizing.
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QSOX1 and TAC induced- ADHF in rats
Malha Sadoune [Orateur], Guillaume Coutance, Nicolas Bihry, Régine 
Merval, Evelyne Polidano, Alain Cohen- Solal, Alexandre Mebazaa, Jane- 
Lise Samuel
Hôpital Lariboisière, INSERM U942, Paris Cedex 10, France
Natriuretic peptides are routinely used to diagnose heart failure (HF), 
nevertheless new biomarkers are needed to improve diagnosis of acute decom-
pensated heart failure (ADHF). Applying a proteomics strategy on plasma, 
Quiescin Q6 (QSOX1) emerged as a promising marker to differentiate 
dyspnea caused by ADHF from other syndroms. Our aim was to get insights 
into the pathophysiological conditions leading to altered expression of QSOX1 
through the use of ADHF model rats and modulation of its expression through 
epigenetic pathway.
Methods: We use thoracic aortic constriction (TAC) in 3 week- old male 
rats, a model that rapidly progresses from cardiac hypertrophy to ADHF. TSA, 
an HDAC inhibitor (Sigma) was injected daily IP (8mM/kg) from day 12 to 
28 after surgery (TAC- TSA). Echocardiography was performed by day 12 & 
28. Anatomical data were recorded. mRNA levels of QSOX1 (S and L forms) 
was measured by RT- qPCR with other transcripts (MyHC7, ANP, BNP, IL10, 
TNFα), that of proteins by Western- Blot.
Results: Qsox1- L,- S mRNAs were up- regulated (x4; p<0.05) in TAC- LV 
12 days after surgery together with depressed LV shortening fraction. BNP 
mRNAs show an earlier rise (x2; p<0.05) at 4.5 days. QSOX1 mRNA level 
was also up- regulated in the left atria (x2; p<0.05) by day 56, the time when 
LA hypertrophy is maximum and AHF is truly developed. Of note all other 
tissues, so far tested (liver, kidney, lung), expressed similar QSOX-1 level 
whatever groups and time. The data indicate that QSOX1 induction in both the 
LV and the LA rats is associated with ADHF.
2 week- TSA treatment that decreased cardiac hypertrophy (p<0.05 versus 
TAC), increased QSOX1L expression in TSA- TAC rats (p<0.05 versus TAC) 
in heart and tended to decrease BNP level. 
Conclusion: Studies in rat models show that QSOX1 expression is induced 
at the early stage of pressure overload- induced ADHF and enhanced by bene-
¿ cial epigenetic modulation. The data suggest that QSOX1, the new bio-
marker of ADHF, plays a role in the process.
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